Skip to main content

Corcept Therapeutics: Discounted Biotech Company Offers Exceptional Risk Profile And Lucrative Proprietary Pipeline

Corcept is a rare low-risk/high-reward investment opportunity in the Biotechnology industry. Total 2018 revenues of $250-270 million represent 90% CAGR over the past 5 years. DCF and comp analysis indicate shares are currently discounted by 35%.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.